Chengdu Zenitar Biomedical Technology Co., Ltd
19
8
10
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 19 trials
100.0%
+13.5% vs industry average
11%
2 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis
Role: lead
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
Role: lead
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Role: lead
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Role: lead
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Role: lead
A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
Role: lead
A Clinical Study of ZL-85FA Tablets
Role: lead
Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative
Role: lead
ZL-82 Double-blind Clinical Trial
Role: lead
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Role: lead
A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets
Role: lead
A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects
Role: lead
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Role: lead
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Role: lead
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
Role: lead
Phase I Clinical Study of ZL-82 Tablets
Role: lead
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Role: lead
Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection
Role: lead
Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors
Role: lead
All 19 trials loaded